US Biotechnology company ImmusanT, Inc.
has discontinued the Phase 2 global study for its lead candidate, Nexvax2®, intended as a treatment for coeliac disease.
Thanks for dropping by at the Gluten Free Expo Brisbane, presented by Coeliac Australia. The two-day Gluten Free Expo was an annual celebration of Australia’s best gluten-free food producers.
Saturday 15 & Sunday 16 June 2019 9am – 4pm Daily